Policymakers & Community Leaders
Patients & Caregivers

Tennessee Recovery Oriented Compliance Strategy (TN ROCS)

Source: Legislative Analysis and Public Policy Association

The Tennessee Recovery Oriented Compliance Strategy (TN ROCS) program provides individualized treatment plans, supervision, and judicial oversight to individuals with a demonstrated need for mental health or substance use disorder treatment but do not qualify for inclusion in a drug court program.

External Website
Policymakers & Community Leaders
Patients & Caregivers

Recovery Oriented Compliance Strategy (ROCS): Latest Tool in Opioid Fight

Source: Tennessee State Courts

The Tennessee Recovery Oriented Compliance Strategy (TN ROCS) program serves drug offenders who have an urgent need for treatment but do not meet the criteria to qualify for participation in a Drug Recovery Court program.

External Website
Policymakers & Community Leaders
Payers & Providers
Patients & Caregivers

Motherhood in Love and Struggle: Lessons from the Camden Coalition’s Camden Delivers Program

Source: Camden Coalition of Healthcare Providers

This report describes a complex care management program for pregnant women with a diagnosis of substance use disorder in Camden, New Jersey. The program, called Camden Delivers, enrolled 46 pregnant or postpartum women who were involved with the child welfare system into the care management program.

Document
Policymakers & Community Leaders
Patients & Caregivers

Reunifying Families with Substance Use Disorder

Source: National CASA/GAL Association

This 8 page overview details strategies promoting the reunification of families when a parent has a substance use disorder. This report explains why prioritizing family unification is important and lists 10 action steps government agencies and community organizations can take to support strong, healthy families.

Document
Policymakers & Community Leaders
Patients & Caregivers

Civil Legal Aid Helps Those Affected by the Opioid Crisis

Evidence Ranking: Promising

Source: The Justice in Government Project and the National Legal Aid & Defender Association

This 3 page briefing paper discusses the role legal aid services can play in helping address the impact of the opioid crisis on individuals, families, and communities.

Document
Policymakers & Community Leaders
Payers & Providers
Patients & Caregivers

The Opioid Crisis and the Hispanic/Latino Population: An Urgent Issue

Source: Substance Abuse and Mental Health Services Administration

This report details how the opioid crisis has affected the Hispanic/Latino population in the US. It includes data on opioid use in this community and a discussion of the socio-cultural factors associated with accessing services including facilitators and barriers to accessing appropriate prevention, treatment, and recovery services and supports.

Document
Policymakers & Community Leaders
Payers & Providers
Patients & Caregivers

New Mexico Statewide Standing Order for Registered Pharmacist Naloxone

Source: New Mexico Department of Health

The New Mexico statewide standing order authorizes registered pharmacists in the state to dispense naloxone to any person who uses an opioid, regardless of how the opioid is used or obtained, or to any person in a position to assist a person at risk of experiencing an opioid overdose.

Document
Policymakers & Community Leaders
Payers & Providers
Patients & Caregivers

Federal Grantees May Now Use Funds to Purchase Fentanyl Test Strips

Source: Substance Abuse and Mental Health Services Administration

The Substance Abuse and Mental Health Services Administration and the Centers for Disease Control and Prevention announced that federal funding may be used to purchase rapid fentanyl test strips (FTS). FTS can be used to determine if drugs have been cut or mixed with fentanyl which greatly increases the risk of overdose death.

External Website
Policymakers & Community Leaders
Payers & Providers
Patients & Caregivers

Approval of Higher Dosage of Naloxone Nasal Spray to Treat Opioid Overdose

Source: U.S. Food and Drug Administration

In April 2021, the FDA announced approval of an application for a produce to deliver an 8 milligram (mg) dose of naloxone; previous approvals had been granted for products delivering 2 mg and 4 mg of naloxone. The approval was granted to provide an additional option for the treatment of opioid overdose.

External Website